Status:
RECRUITING
The Role of Obesity in Severe COVID-19 Pathophysiology
Lead Sponsor:
Franciscus Gasthuis
Conditions:
COVID-19
Antibody COVID-19
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in millions of deaths worldwide. As of 2024, the SARS-CoV-2 O...
Detailed Description
This is a mono-center, prospective cohort study involving both a test group and a control group. The test group comprises patients with obesity eligible for bariatric surgery at Franciscus Hospital, w...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Cohort 1 (obesity cohort)
- ≥18 and ≤65 years of age
- BMI ≥30 kg/m²
- Patient of Franciscus Hospital
- Cohort 2 (control cohort)
- ≥18 and ≤65 years of age
- BMI \<25 kg/m²
- Healthcare workers of Franciscus Hospital
- Exclusion Criteria (for both cohorts):
- Acute infection or current systemic immunological disorders
- Use of immune-modulatory medication (i.e., corticosteroids and biologicals)
- Hormonal therapy
Exclusion
Key Trial Info
Start Date :
April 22 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 22 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06968442
Start Date
April 22 2025
End Date
April 22 2026
Last Update
May 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Franciscus
Rotterdam, South Holland, Netherlands, 3045PM